Myeloid Therapeutics

[Myeloid Therapeutics @MyeloidTx]

https://t.co/Xt2NHUCqaG

[Myeloid Therapeutics @MyeloidTx]

Next week at #JPM2025, our CEO Daniel Getts, Ph.D., will present on Wednesday, January 15, 2025, at 8:30 am PT. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo #mRNA engineering technology.

https://t.co/TvHmXvVWrs

[Myeloid Therapeutics @MyeloidTx]

@MyeloidTx will participate in the #JefferiesHealthcare Conference beginning Nov. 19. Members of the management team will meet with investors one-on-one and conduct B-to-B meetings to discuss our industry-leading in vivo mRNA engineering technology.

https://t.co/JUcdhEzgzp

[Myeloid Therapeutics @MyeloidTx]

At 9:30 am today, @MyeloidTx's CEO, Daniel Getts, PhD, is speaking at #BioEurope in the Immuno-Oncology session. We look forward to showcasing our science and mRNA-based clinical pipeline.

Learn more here: https://t.co/3T9GvaopRZ

#Biotech #mRNA

[Myeloid Therapeutics @MyeloidTx]

Thank you, #ESMO2024 organizers, for showcasing Myeloid's Trials-in-Progress poster on the MYE Symphony Study (NCT05969041), a First-in-Human Phase 1 trial evaluating our innovative MT-302 program. MT-302 is our lead in vivo #mRNA CAR targeting TROP2+ epithelial malignancies.

[Myeloid Therapeutics @MyeloidTx]

We are excited to continue to tell the @MyeloidTx story at several upcoming conferences in September and October.

More details can be found here: https://t.co/YAJZ7YeEHV

#biotech #mRNA

[Myeloid Therapeutics @MyeloidTx]

W are looking forward to participating in the @Barclays Biotech: 1x1 Private Company Symposium on August 7, 2024. Members of the management team will meet with investors one-on-one to discuss our industry-leading in vivo mRNA engineering technology.

https://t.co/2qnJaxuo6K

[Myeloid Therapeutics @MyeloidTx]

At Myeloid, our mission is to develop RNA therapeutics to conquer cancer - dosing our first patient with MT-303 in our Phase 1 study brings us one step closer to achieving our goal.

Learn more about our clinical trials here:  https://t.co/TUdZyCwGbh

#oncology

[Myeloid Therapeutics @MyeloidTx]

#BreakingNews  We announced today that we are dosing patients with our second in vivo mRNA CAR, MT-303, a novel GPC3 targeting RNA CAR, in a Phase 1 study for the treatment of advanced hepatocellular carcinoma, the most prevalent form of liver cancer.  
https://t.co/kPBROs1C5x

[Myeloid Therapeutics @MyeloidTx]

Jerome Chal, Myeloid's SVP and Head of CMC, presents today in Boston at the 2024 Cell & Gene Therapy Summit. He will describe Myeloid's acceleration of in vivo programming of immune cells for patients combating solid tumors. 

More detail here: https://t.co/4flYptGE5m

#CGT2024

[Myeloid Therapeutics @MyeloidTx]

Next week, we're headed to the #JefferiesHealthcare Conference Private Biotech Day! The @MyeloidTx management team will be meeting with investors 1:1 to discuss our industry-leading in vivo mRNA engineering technology & expanding clinical pipeline.

https://t.co/S4SxlO381Y

[Myeloid Therapeutics @MyeloidTx]

This week at #APVIC 2024, our CSO, Robert Hofmeister, Ph.D., showcased Myeloid's cutting-edge in vivo mRNA engineering technology and in vivo clinical pipeline. 

More details can be found here: https://t.co/NUi8lGYwm9

#APVIC24 #mRNA #invivo #biotech

[Myeloid Therapeutics @MyeloidTx]

Our in vivo mRNA CAR, MT-302, continues progressing well in the ongoing clinical studies, with plans for expanded clinical use. Daniel Getts, PhD, our CEO, shared we're expanding plans for MT-302’s clinical use, given several inherent product advantages for patients. #ASGCT2024

[Myeloid Therapeutics @MyeloidTx]

This week, @MyeloidTx is in Baltimore for #ASGCT2024. We are presenting multiple posters showcasing the clinical progress of MT-302, the world’s first in vivo mRNA CAR drug candidate, and our CREATE platform technology for precision RNA-mediated gene editing and delivery.

[Myeloid Therapeutics @MyeloidTx]

Join us at @AACR Mon, April 8th when we share data supporting MT-302, the world’s first clinical stage in vivo mRNA CAR drug development candidate and we showcase our diverse mRNA platform. More info: https://t.co/oa3zXOXueZ #AACR24

[Myeloid Therapeutics @MyeloidTx]

On #internationalwomensday2024 join us in celebrating the incredible women @MyeloidTx who are driving innovation and the countless women around the world who inspire us all! We are proud to have such an extraordinary group of women on our team. #inspireinclusion #womeninscience

[Myeloid Therapeutics @MyeloidTx]

Mark your calendars for Myeloid's updates on our RNA Immunotherapies at the #AACR24 next month. Join us to learn about our cutting-edge approach and its potential impact on cancer immunotherapy https://t.co/UjKLxrm6Ef

[Myeloid Therapeutics @MyeloidTx]

On #RareDiseaseDay, @MyeloidTx stands with the rare disease community, celebrating resilience and driving innovation. This year, hope abounds for the impact of our CREATE platform – a leap forward, making gene editing possible & accessible; Learn more: https://t.co/ng13ROnBEh

[Myeloid Therapeutics @MyeloidTx]

On #WorldCancerDay, we honor the millions of fighters, celebrate survivors, and remember the brave souls we've lost. @Myeloid, we remain committed to leveraging science and tech to help save lives. #CancerAwareness #InnovationAgainstCancer

[Myeloid Therapeutics @MyeloidTx]

As we embark on the next exciting phase of advancing our pipeline of programs, we are excited to welcome Robert Hofmeister Ph.D., as our Chief Scientific Officer. His expertise and stellar track record, will drive innovation and scientific excellence https://t.co/OthaF5QfCf